Clinical development platforms typically evolve with technology advances and scientific breakthroughs. Notably, the COVID-19 pandemic accelerated the adoption of digital technologies, data science, analytics, and automation tools, enabling remote services and preserving the continuity of care.
A unified clinical development platform with improved data architecture and analytics capabilities can accelerate the drug development process and enrich the experience for sponsors, patients, and physicians. In recent years, the industry has pivoted from questioning the existence of end-to-end platforms to creating a near-term vision for adopting such platforms.
Everest Group’s Clinical Development Platforms Products PEAK Matrix® Assessment 2022 looks at the vendor landscape of clinical development platforms and presents in-depth analysis and insights on these platforms. We assess the capabilities of 22 clinical development platform vendors and map them on the Everest Group PEAK Matrix®, a composite index of distinct metrics related to a vendor’s capability and market impact.
Scope
Industry: life sciences
Geography: global
Contents
This report features 22 clinical development product vendors’ profiles and includes:
Assessment of the product vendors on several capability and market success-related dimensions
Detailed profiles of each product vendor, featuring case studies and recent developments
The COVID-19 outbreak compelled the life sciences industry to innovate and transform digitally. However, the current global macroeconomic and socio-political uncertainty, coupled with increasing research and development IT expenditure, have created…
